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Background: Subepithelial hypervascularity and angiogenesis in the airways are part of structural
remodelling of the airway wall in asthma, but the effects of inhaled corticosteroids (ICS) on these have not
been explored. Increased vascularity in asthma may contribute to a number of functional abnormalities. A
study was undertaken to explore angiogenic modulation by ICS and its likely regulation via vascular
endothelial growth factor (VEGF), its receptors and the angiopoietins.
Methods: A placebo-controlled intervention study with ICS in asthma was performed, examining vascularity,
VEGF, its receptors (VEGFR1 and VEGFR2), and angiopoietin-1 (Ang1) to assess which of these factors were
changed in the asthmatic airways after ICS treatment. Airway wall biopsy specimens, lavage fluid and cells
were obtained from 35 patients with mild asthma randomised to receive ICS or placebo for 3 months, after
which bronchoscopic examination and sample collection were repeated. Immunohistochemistry and image
analysis were used to obtain quantitative measures of vessels, angiogenic sprouts, VEGF, VEGFR1, VEGFR2
and Ang1 staining in airway biopsy specimens. ELISA was used to assess VEGF concentrations in the lavage
fluid.
Results: Vessel, VEGF and sprout staining were decreased after 3 months of ICS treatment. VEGF levels
remained unchanged. VEGF receptors and Ang1 staining were not reduced after treatment.
Conclusions: The findings of this study support an effect of ICS in downregulating angiogenic remodelling in
the airways in asthma, associated with decreasing VEGF activity within the airway wall. The environment of
the airways after treatment with ICS, with changes in the balance between VEGF, its receptors, Ang1 and
sprouts, appears to be less angiogenic than in untreated asthma.
A
sthma is characterised by variable airflow obstruction,
airway hyper-responsiveness, chronic airway inflamma-
tion and airway wall structural remodelling. Inhaled
corticosteroids (ICS) are the most effective treatment currently
available for inducing symptomatic control, and have become
the mainstay of modern asthma treatment.1 ICS suppress the
chronic inflammation of asthma and improve airway hyper-
responsiveness and lung function.2 3 Their main advantage is
high efficacy combined with few systemic side effects compared
with oral steroids such as prednisolone.4 The effects of current
treatment regimens on structural airway changes in asthma are
less well established. We have recently shown beneficial effects
on subepithelial reticular basement membrane scarring,
although this required more protracted treatment compared
with effects on inflammation.5
Airway remodelling is believed to occur in concert with, or as
a result of, ongoing airway damage resulting from airway
inflammation. Bronchial hyper-responsiveness (BHR) is char-
acteristic of asthmatic airways and seems to be related equally
to airways inflammation and remodelling.5 Anti-inflammatory
corticosteroids reverse BHR, and this seems to be due to effects
on both airway inflammation and remodelling. However, the
temporal changes in the pathological domain of asthma may be
different, although there are as yet few data at this detailed
level.
Previous work from our group and laboratory has shown that
the airways of steroid-naive asthmatics have more vessels and a
greater percentage area of vasculature in the lamina propria
immediately below the epithelium than normal control
subjects.6 Hypervascularity of the subepithelial lamina propria
in asthma airways is beginning to attract increased attention,
with several recent studies having investigated its contribution
to airway pathology in asthma.7 8 There are a small number of
studies on the effects of treatment with ICS.9 In cross-sectional
studies the increased vascular indices in asthma have been
related to functional changes such as lung function, BHR and
dose of ICS.10 11
Vascular endothelial growth factor (VEGF) is a multifunc-
tional growth factor with potent actions on vascular endothelial
cells, inducing mitogenesis, increased endothelial permeability
and enhanced cell migration. In asthma, VEGF has been
implicated in airway vascular remodelling either by increasing
vascular permeability and tissue oedema and/or stimulation of
new blood vessel growth.9 Both effects may lead to increased
airway wall thickness and airflow limitation, especially in the
presence of enhanced contraction of the surrounding muscle
layer.12 Angiopoietin-1 (Ang1) is another angiogenic growth
factor which acts both in series with and subsequent to VEGF
stimulation. It helps to maintain and stabilise mature vessels by
promoting interactions between endothelial cells and surround-
ing support cells such as pericytes.13 14 Thus, VEGF and Ang1
are likely to complement each other in angiogenic processes
within the airways of asthmatics.
In the present study we have continued our examination of
vascular ‘‘sprouts’’ which we reported recently.15 We have
suggested that these cystic structures in the vascular wall of
airway vessels may be newly forming vessels or, at least,
indicators of enhanced remodelling processes. We previously
reported differences between patients with asthma and controls
Abbreviations: Ang1, angiopoietin-1; BAL, bronchoalveolar lavage; BHR,
bronchial hyper-responsiveness; FP, fluticasone propionate; GMA, glycol
methacrylate; ICS, inhaled corticosteroids; VEGF, vascular endothelial
growth factor; VEGFR1, VEGFR2, vascular endothelial growth factor
receptors R1 and R2
314
www.thoraxjnl.com
in these structures, and have now examined the effects of ICS
on these sprouts.
The effect of ICS on airway mucosal vascularity in patients
with asthma has not been fully established. No studies to date
have examined the influence of ICS on VEGF or Ang1 or their
potential contributions to microvascular remodelling in
asthma. In this study we aimed to determine whether high
dose ICS (750 mg fluticasone propionate (FP) twice daily) at 3
and 12 months of treatment would reverse changes observed in
the airway microvasculature and the angiogenic factors VEGF
and Ang1, as well as VEGF receptors VEGFR1 and VEGFR2, in
patients with mild to moderate steroid-free asthma. In this
‘‘test of concept’’ study we hypothesised that treatment with
high dose ICS would significantly reduce subepithelial vascu-
larity and associated growth factors, especially VEGF.
METHODS
Thirty-five patients with mild to moderate symptomatic atopic
asthma were recruited. All fulfilled ATS criteria for asthma
which had been well documented for at least 12 months. Their
mean (SD) age was 39 (13) years (range 20–70). None were
current smokers; 16 were ex-smokers who had given up a
median of 16 years (interquartile range 6–22 years) before
recruitment. There was no clinical or physiological evidence of
smoking-related disease in any participant in the study.
Subjects were using only inhaled salbutamol for relief of
symptoms and no ‘‘preventer’’ medication: in particular no
subject had received treatment with regular ICS or inhaled long
acting b2 agonist for at least 12 months before the study. Only
one subject had received a short course of oral corticosteroid
treatment previously, but not within the last 3 months. Full
details of the clinical status and study parameters can be found
in our recently published work.15
Following recruitment there was a 2 week run-in period
during which the subjects were continued on salbutamol alone
as needed for symptomatic relief. Following this, bronchoscopic
examination was performed with a 180 ml standardised
bronchoalveolar lavage (BAL) and up to six airway biopsy
specimens were taken.
The subjects were then randomised to one of the following
treatment groups: FP 750 mg twice daily via metered dose
inhaler or placebo (twice daily) via an identical metered dose
inhaler. Of the 34 recruited patients, only one withdrew from
the active treatment group. Bronchoscopy and airway sampling
were again performed after 3 and 12 months of treatment. We
were unable to obtain sufficient samples at 12 months to give
statistically relevant data as only seven subjects remained in the
study, which was insufficient for meaningful statistical power.
However, qualitative examination of the data strongly sug-
gested that there were no further changes between the 3 and
12 month periods in vessels or growth factors, so our analysis
has been restricted to the 3 month data.
For bronchoscopic examination, subjects were premedicated
with intravenous 0.4 mg atropine and 5–15 mg midazolam.
Nebulised salbutamol (5 mg) was also given 15 minutes before
bronchoscopic examination. Lignocaine (4%) was applied
topically to the nose, pharynx, and larynx and 2% lignocaine
below the cords in 2 ml aliquots as required up to a maximum
dose of 6 ml. Subjects were monitored using pulse oximetry
and administered oxygen during the procedure. All airway
pathological end points were read blind to any clinical or
treatment information, and admixed with normal control
material taken from other concurrent studies (data not shown).
The study was approved by the institutional ethics committee
and all subjects gave written informed consent.
Vessel staining and quantification
Biopsy specimens were embedded into the hydrophilic polymer
glycol methacrylate (GMA). Coded blocks were cut on a semi-
thin resin microtome (Leica RM 2310, Leica Microsystems,
Nussloch, Germany) using glass triangular knives. The 2 mm
sections were then floated on water and adhered to silanised
slides. Immunohistochemical staining was performed using
anti-collagen type IV antibody to outline the endothelial
basement membrane of airway vasculature. Total numbers of
vessels per unit area were counted in quantifiable lamina
propria to a depth of 150 mm below the epithelial basement
membrane. Angiogenic ‘‘sprouts’’ (fig 1) were simultaneously
counted and the total number of sprouts per unit area and the
mean number of sprouts per vessel were recorded.
Growth factor detection
Biopsies were fixed in 10% formalin for 2 hours and then
embedded in paraffin wax. Blocks were cut on a Leica RM2155
microtome (Leica Microsystems) at 3 mm thickness and
sections were adhered to silanised glass slides. Extensive
preliminary studies showed that GMA was poor for these
immunostaining end points. Staining was performed with
monoclonal antibodies for VEGF (R&D Systems, Minneapolis,
Minnesota, USA), VEGFR1, VEGFR2 (Santa Cruz Biotech,
Santa Cruz, California, USA) and Ang1 (Jomar Diagnostics,
Figure 1 Immunohistochemical staining of vascular ‘‘sprouts’’.
Endobronchial biopsy specimens obtained from asthmatic subjects were
immunostained with collagen type IV antibody to highlight the endothelial
basement membrane of blood vessels located within the lamina propria.
‘‘Sprouts’’ were defined as the unusual vessel-like spaces located within the
lining of the vessel wall (arrows).
Table 1 Mean vessel, growth factor and receptor staining
levels per mm2 at baseline
Placebo ICS Significance
Vessels 374 (29) 466 (37) NS
VEGF 565 (76) 564 (81) NS
VEGFR1 361 (29) 324 (19) NS
VEGFR2 514 (114) 443 (44) NS
Ang1 471(49) 532(42) NS
ICS, inhaled corticosteroid; VEGF, vascular endothelial growth factor;
VEGFR1, VEGFR2, vascular endothelial growth factor receptors 1 and 2;
An1, angiopoietin-1.
There were no significant differences between the two groups.
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Stepney, South Australia, Australia) staining. For both types of
preparation an ABC avidin-HRP kit (Vectastain Elite ABC Kit,
VECTA Laboratories, Burlingame, California, USA) was used
for secondary antibody binding and colour resolution. Growth
factor staining was predominantly associated with vessels and
quantified as stained vessels per unit area. The concentration of
VEGF in BAL supernatant was measured using the QuantiGlo
human VEGF immunoassay (R&D Systems, USA).
Quantitative analysis of the biopsy sections was performed
with a Leika DM LB microscope (Leica Microsystems), Dage-
MTI DC200 one-chip video camera and Image Pro V4.1 (Media
Cybernetics, Sliver Spring, Maryland, USA) software.
Analysis of data
Differences between treatment groups were analysed using the
Student’s t test either on the raw data (if parametric) or on
log10 transformed data (if non-parametric). All data were
expressed as means (standard error of the mean (SEM)).
Differences were considered significant at p,0.05. All data
were compared with baseline values—that is, as the percentage
change from baseline in either the placebo or treatment groups
after treatment. These differences were used to compare the
placebo and treatment groups using standard t tests.
RESULTS
Baseline data
To reduce statistical error after treatment, the placebo and ICS
treated groups were examined at baseline for statistical
differences in vessel numbers, VEGF staining and receptor
levels and Ang1 levels. No differences were found between the
groups before treatment. These data are summarised in table 1.
Vessel numbers
After 3 months of treatment with ICS the number of vessels/
mm2 in airway biopsy specimens was significantly reduced (ICS
group: –122 (31) vessels/mm2, placebo group: +10 (41) vessels/
mm2; p = 0.002). In percentage terms this equated to a decrease
of 25 (5)% in the ICS group (p,0.01) compared with an
increase of 7 (8)% in the placebo group (fig 2).
VEGF staining and levels
Treatment with ICS had a significant effect on VEGF staining in
biopsy sections. In the ICS group VEGF staining was reduced by
–238 (141) stained vessels/mm2 (245 (7)%) compared with a
significantly smaller reduction in the placebo group of –119
(128) stained vessels/mm2 (223 (9)%; p = 0.04, fig 3).
However, concentrations of VEGF in asthmatic BAL super-
natant specimens were unchanged after 3 months of treatment
with either placebo or ICS (fig 4).
VEGF receptor and Ang1 staining
No significant absolute changes were observed in immunos-
taining for VEGFR1 or VEGFR2 in bronchial biopsy specimens
from placebo or ICS treated subjects (figs 5 and 6). Similarly,
the absolute number of positively stained Ang1 vessels/mm2 did
not change significantly at 3 months in either group (fig 7).
Examining the relative staining for growth factors and
receptors as a ratio of the number of vessels, we found that
the percentage of total vessels/mm2 stained with VEGF was
lower with ICS (p = 0.04 within group), but not relative to
coincidental changes in placebo. The percentage of vessels
stained with VEGFR2 showed a trend towards an increase after
treatment (p = 0.09) relative to placebo, as did Ang1/vessel
(p = 0.07). The percentage of vessels stained with VEGFR1 was
somewhat increased, but similar relative to placebo (table 2).
Treatment with ICS significantly reduced the number of
sprouts per vessel from 4.72 (0.61) at baseline to 3.42 (0.68)
after 3 months of treatment (p,0.01); again, no significant
changes were observed in the placebo group. Analysis of the
percentage changes between both treatment groups showed
that ICS significantly reduced the number of sprouts per vessel
from baseline to 3 months compared with placebo (ICS –29.1
(5.8)% vs placebo +23.6 (18.7)%; p = 0.02, fig 8).
DISCUSSION
Inhaled corticosteroids are the most potent anti-inflammatory
agents available for the treatment of asthma.16 Their total effect
Figure 2 Percentage change in stained vessels per mm2 lamina propria in
airway biopsies relative to placebo after treatment with inhaled
corticosteroid (ICS). Bars are standard errors.
Figure 3 Percentage change in vascular endothelial growth factor (VEGF)
stained vessels per mm2 of lamina propria in airway biopsies relative to
placebo after treatment with inhaled corticosteroid (ICS). Bars are standard
errors.
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Figure 4 Vascular endothelial growth factor (VEGF) levels in
bronchoalveolar lavage supernatant before and after 3 months of
treatment with inhaled corticosteroid (ICS) or placebo.
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is known to be related to many factors including the
attenuation of inflammatory cell numbers, function and
activation; stabilisation of vascular leakage; a decrease in
mucus production; and an increase in b-adrenergic response.17
In addition, we have previously shown a decrease in airway scar
collagen deposition, but only after a 12 month period of
treatment.18 In this study we have shown that 3 months of
treatment with high dose FP (750 mg twice daily) was able to
reduce the total number of vessels within the lamina propria of
airways in ICS treated asthmatic patients. Twelve months of
treatment had no further effect.
Concomitant with the reduction in vessel numbers during
the 3 month initial treatment period, ICS also decreased VEGF
immunostaining, but proportionately to the decrease in vessel
numbers. In contrast, no ICS-related changes were observed in
BAL fluid concentrations of VEGF. There was no absolute
change in VEGF receptors (VEGFR1 or VEGFR2) or Ang1
immunostaining but, in relation to the change in vessel
numbers, expressions of VEGFR2 and Ang1 were slightly
higher after treatment. We also observed a proportionate
decrease in the numbers of angiogenic sprout-like structures
within the vascular wall of vessels after ICS treatment, as
further evidence of ICS-induced downregulation of vascular
remodelling.
The relationship between ICS dosage and subepithelial
vascularity has been examined previously by our group.11 We
found an inverse relationship between ICS dosage and airway
wall vascularity in patients with asthma of comparable clinical
disease activity, with higher dose beclomethasone dipropionate
treatment (>800 mg/day) being associated with reduced vessel
numbers. In addition, in many of those receiving high dose ICS,
the vessel numbers fell within the normal range of healthy
controls, a finding also reported by others after 6 weeks of high
dose FP treatment.18 Together, these findings suggest that
higher doses of ICS may be required to consistently reverse
airway hypervascularity in asthma.
This study supports these previous findings and further
examines the contribution of the angiogenic factors VEGF and
Ang1, as well as VEGFR1 and VEGFR2, and the potential role
that they may have in the microvascular remodelling process in
asthma. Our data suggest that VEGF expression within the
airway wall is responsive to ICS, and this may be the means by
which ICS causes regression of hypervascularity in the airway
wall. While VEGF vessel staining was reduced in relation to the
absolute number of vessels after treatment, no parallel changes
were observed in Ang1, VEGFR1 or VEGFR2 immunostaining.
In examining the ratios of these factors per vessel, we observed
an indication that VEGFR2 and Ang1 expression could be
proportionately increased after treatment. Although specula-
tive, given the data, relative increases in VEGFR2, the active
VEGF receptor, and Ang1, a vascular stabilising factor, might
suggest that conditions in the airways after ICS treatment are
less angiogenic.
VEGF concentrations did not change in the BAL fluid in ICS-
treated asthmatics. This disparity with VEGF staining may be
explained by regional differences in the airway distribution
from which the specimens were obtained: endobronchial biopsy
specimens were obtained from proximal airways (generations
3–4) whereas BAL fluid specimens may better sample the
smaller peripheral airways. Regional differences in FP deposi-
tion between large and small airways due to the size of the FP
particles may account for the observed disparity in the results.
Figure 5 Percentage change in vascular endothelial growth factor
receptor 1 (VEGFR1) stained vessels per mm2 lamina propria in airway
biopsies relative to placebo after treatment with inhaled corticosteroid
(ICS). Bars are standard errors.
Figure 6 Percentage change in vascular endothelial growth factor
receptor 2 (VEGFR2) stained vessels per mm2 lamina propria in airway
biopsies relative to placebo after treatment with inhaled corticosteroid
(ICS). Bars are standard errors.
Figure 7 Percentage change in angiopoietin-1 (Ang1) stained vessels per
mm2 of lamina propria in airway biopsies relative to placebo after
treatment with inhaled corticosteroid (ICS). Bars are standard errors.
Figure 8 Percentage change in number of vascular sprouts per vessel
relative to placebo after treatment with ICS. Bars are standard errors.
ICS, VEGF and angiogenesis in asthma 317
www.thoraxjnl.com
Nevertheless, BAL fluid levels of VEGF were strongly associated
with subepithelial vascularity at baseline.15 After 3 months of
ICS treatment, however, this relationship was no longer evident
(data not shown). This might suggest that VEGF levels in BAL
fluid reflect some clearance mechanism by which VEGF is
moved out into the airway lumen after ICS treatment, away
from angiogenic receptors. Such ‘‘luminal clearance’’ mechan-
isms for airway pro-inflammatory cytokines have previously
been suggested.19
ICS-induced reduction of the subepithelial vasculature within
the airway wall may have considerable functional implications,
given that the microvascular bed is a substantial component of
the airways (,20% of the area of the airway wall). Even small
alterations to the thickness of the inner airway wall can
contribute to enhanced airway narrowing in asthma.12 Despite
this, the reduction in subepithelial vascularity after ICS treat-
ment in this study was not directly proportional to clinical or
physiological improvement in this study (regression not shown),
nor in several other studies.10 18 20 We and others have found such
an association cross-sectionally in asthma and have shown
significant inverse correlations between subepithelial vascularity
and FEV1 and BHR, suggesting that the degree of vascularity and
potential capacity for engorgement of the airway wall may play a
role in diminished lung function and the pathogenesis of BHR in
asthma.11 21 Thus, the acute physiological state of the airway may
be an important factor in demonstrating the importance of
angiogenesis—that is, whether the vessels themselves are dilated
and/or engorged as part of an acute inflammatory challenge, and
whether the airway muscle deep to the vascular plexus is being
constricted. Lack of a relationship between vessels and other
manifestations of asthma under resting and well controlled
conditions may be less meaningful.
Further evidence of the modulation of airway vascularity by
ICS is demonstrated in the observed reduction in vascular
‘‘sprouts’’ after ICS treatment. In a previous paper15 we showed
differences between control and asthmatic subjects in these
vascular structures but were unable to determine their exact
nature. We have now shown that they are sensitive to ICS
treatment and are greatly reduced in an environment where
total vessel numbers are decreasing with treatment. While it is
possible that these sprouts are not angiogenic structures per se,
there can be little doubt that they are at least an indicator of
vascular remodelling.
This study supports the hypothesis that high dose ICS
downregulates microvascular angiogenic remodelling in asthma.
The observed reduction in subepithelial vascularity following
3 months of treatment with high dose FP (750 mg twice daily)
was associated with a concomitant and proportionate reduction
in VEGF-positive vessels per unit area, and a reduction in
angiogenic sprouts per vessel. Further, the relationships between
VEGF, both stained within airway vessels and in the BAL fluid,
were quite different after ICS treatment compared with baseline.
These changes, as well as the relative changes to VEGF receptors
and Ang1 staining, suggest subtle re-setting and probable
stabilisation of angiogenic control mechanisms in the airway
wall with ICS treatment.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
B N Feltis, D W Reid, E H Walters, Cardio-Respiratory Research Group,
University of Tasmania, Hobart, Australia
D Wignarajah, Department of Medicine, Monash University, Melbourne,
Australia
C Ward, Applied Immunobiology and Transplantation Group, University of
Newcastle upon Tyne, UK
R Harding, Department of Anatomy and Cell Biology, Monash University,
Australia
Competing interests: None
REFERENCES
1 Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new
mechanisms for old drugs. N Engl J Med 2005;353:1711–23.
2 Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist,
terbutaline, with an inhaled corticosteroid, budesonide, in newly detected
asthma. N Engl J Med 1991;325:388–92.
3 Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on
airway inflammation and symptoms in asthma. Am Rev Respir Dis
1992;145:669–74.
4 Derendorf H. Hochhaus G, Meibohm B, et al. Pharmacokinetics and
pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol
1998;101(4 Pt 2):S440–6.
5 Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane
thickening and bronchial hyperresponsiveness in asthma. Thorax
2002;57:309–16.
6 Orsida BE, Ward C, Li X, et al. Effect of a long-acting beta2-agonist over three
months on airway wall vascular remodeling in asthma. Am J Respir Crit Care
Med 2001;164:117–21.
7 Chetta A, Zanini A, Foresi A, et al. Vascular endothelial growth factor up-
regulation and bronchial wall remodelling in asthma. Clin Exp Allergy
2005;35:1437–42.
8 Hashimoto M, Tanaka H, Abe S. Quantitative analysis of bronchial wall
vascularity in the medium and small airways of patients with asthma and COPD.
Chest 2005;127:965–72.
9 Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth
factor, basic fibroblast growth factor, and angiogenin immunoreactivity in
asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol
2001;107:295–301.
10 Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma.
Am J Respir Crit Care Med 1997;156:229–33.
11 Orsida BE, Li X, Hickey B, et al. Vascularity in asthmatic airways: relation to
inhaled steroid dose. Thorax 1999;54:289–95.
12 Moreno RH. Hogg JC. Pare PD. Mechanics of airway narrowing. Am Rev Respir
Dis 1986;133:1171–80.
13 Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for
Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55–60.
14 Suri C, McClain J, Thurston G, et al. Increased vascularization in mice
overexpressing angiopoietin-1. Science 1998;282:468–71.
15 Feltis BN, Wignarajah D, Zheng L, et al. Increased vascular endothelial growth
factor and receptors: relationship to angiogenesis in asthma. Am J Respir Crit
Care Med 2006;173:1201–7.
16 Barnes PJ. Inhaled glucocorticoids: new developments relevant to updating of the
asthma management guidelines. Respir Med 1996;90:379–84.
17 Lemanske RF Jr, Busse WW. 6. Asthma. J Allergy Clin Immunol 2003;111(2
Suppl):S502–19.
Table 2 Ratio of stained growth factor to vessel numbers in airway biopsy specimens before
and after treatment with ICS or placebo
Mean vessel staining (pre-ICS) Mean vessel staining (post-ICS) Significance of ICS
treatment change vs
placeboICS (%) Placebo (%) ICS (%) Placebo (%)
VEGF 100 (12) 100 (17) 75 (9) 85 (13) NS
VEGFR1 65 (8) 70 (11) 100 (10) 86 (9) NS
VEGFR2 42 (9) 55 (13) 100 (14) 67 (8) NS (p = 0.09)
Ang1 68 (3) 74 (7) 100 (5) 72 (8) NS (p = 0.07)
ICS, inhaled corticosteroid; VEGF, vascular endothelial growth factor; VEGFR1, VEGFR2, vascular endothelial growth
factor receptors 1 and 2; An1, angiopoietin-1.
VEGF staining at baseline was normalised to 100% and receptor staining is given as a percentage of the respective
vessels counted.
318 Feltis, Wignarajah, Reid, et al
www.thoraxjnl.com
18 Chetta A, Zanini A, Foresi A, et al. Vascular component of airway remodeling in
asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med
2003;167:751–7.
19 Feltis BN, Reid DW, Ward C, et al. BAL eotaxin and IL-5 in asthma, and
the effects of inhaled corticosteroid and beta2 agonist. Respirology
2004;9:507–13.
20 Orsida BE, Ward C, Li X, et al. Effect of a long-acting beta2-agonist over three
months on airway wall vascular remodeling in asthma. Am J Respir Crit Care
Med 2001;164:117–21.
21 Hoshino M, Takahashi M, Takai Y, et al. Aoike N. Inhaled corticosteroids
decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp
Allergy 2001;31:722–30.
bmjupdates+
bmjupdates+ is a unique and free alerting service, designed to keep you up to date with the
medical literature that is truly important to your practice.
bmjupdates+ will alert you to important new research and will provide you with the best new
evidence concerning important advances in health care, tailored to your medical interests and
time demands.
Where does the information come from?
bmjupdates+ applies an expert critical appraisal filter to over 100 top medical journals
A panel of over 2000 physicians find the few ’must read’ studies for each area of clinical interest
Sign up to receive your tailored email alerts, searching access and more…
www.bmjupdates.com
ICS, VEGF and angiogenesis in asthma 319
www.thoraxjnl.com
